Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | MET | P08581 | 4/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | NEK2 | P51955 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14494630 | 0.92 | MET (0.58) | PDE4APDE4BPDE4CPDE4DPKM | |
| SCHEMBL15815401 | 0.90 | CHEK1 (0.70) | PDE4APDE4BPDE4CPDE4DPKM | |
| SCHEMBL2493573 | 0.85 | MET (0.61) | PKMUSP2ALOX15ATMMET | |
| SCHEMBL4125734 | 0.84 | MET (0.68) | MET | |
| SCHEMBL2466162 | 0.84 | MET (0.60) | PKMUSP2ALOX15ATMMET | |
| SCHEMBL2468122 | 0.82 | MET (0.81) | MET | |
| SCHEMBL2465886 | 0.79 | MET (0.55) | METMAPTSMN1; SMN2 | |
| SCHEMBL23297323 | 0.79 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4DPKM | |
| SCHEMBL15815239 | 0.79 | CHEK1 (0.61) | PDE4APDE4BPDE4CPDE4DPKM | |
| SCHEMBL13653057 | 0.77 | PDE4D (0.60) | PDE4APDE4BPDE4CPDE4DPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007065518-A1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | PDE4A 3041/4885PDE4B 3620/4885PDE4C 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.